Svein Mathisen, CEO of BioInvent, responses: ‘We conclude that BI-204 did not meet up with the primary objective lay out in the GLACIER research. Before deciding on the continuing future of BI-204, we and our partner Genentech have to finalize the entire data analysis. We be prepared to offer an update later this year.’.. BioInvent announces data from BI-204 stage IIa study on steady atherosclerotic vascular disease BioInvent International Stomach today announced data from the GLACIER phase IIa research analyzing BI-204 in patients with stable atherosclerotic vascular disease. BioInvent is usually developing BI-204 in collaboration with Genentech, an associate of the Roche Group . The principal endpoint of the scholarly research was the relative modification in inflammatory activity within an index arterial vessel after twelve weeks, as measured by FDG-PET/CT imaging .Weighed against placebo, treatment with alogliptin resulted in similar prices of the principal endpoint, that was a composite of cardiovascular loss of life, myocardial infarction, and stroke , said the seat of the study's steering committee William B. White, MD, from the University of Connecticut School of Medicine in Farmington, Connecticut, USA. The findings could instruction clinicians to select among the many anti-diabetic agents available when treating individuals with type 2 diabetes and very high cardiovascular risk, he suggested.